Recurrent small-artery disease in hyperhomocysteinemia: Widower's stroke syndrome?

Internal Medicine

Volumn 43, Issue 9, 2004, Pages 869-872

  Toyoda, Kazunori ^a   Uwatoko, Takeshi ^a   Shimada, Toshifumi ^a   Hagiwara, Noriko ^a   Fujimoto, Shigeru ^a   Ibayashi, Setsuro ^b   Okada, Yasushi ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Cerebral hemorrhage; Homocysteine; Lacunar infarction; Methylenetetrahydrofolate reductase; Stroke prevention

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CYANOCOBALAMIN; CYTIDINE; FOLIC ACID; HOMOCYSTEINE; MULTIVITAMIN; PYRIDOXINE; THYMINE; TICLOPIDINE;

ADULT; AGE; ARTERY DIAMETER; ARTICLE; BLOOD ANALYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CASE REPORT; FREQUENCY ANALYSIS; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LIFESTYLE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NORMAL VALUE; NUCLEAR MAGNETIC RESONANCE IMAGING; PONS ANGLE; RECURRENT DISEASE; RISK FACTOR; STROKE; THALAMUS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WIDOWER STROKE SYNDROME;

CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; DIET; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; RECURRENCE; WIDOWHOOD;

EID: 5044240634     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.869     Document Type: Article

References (19)

1. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C→ T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 59: 529-536, 2002.
2. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325: 1202, 2002.
3. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332: 286-291, 1995.
4. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 31: 1069-1075, 2000.
5. Sasaki T, Watanabe M, Nagai Y, et al. Association of plasma homocysteine concentration with atherosclerotic carotid plaques and lacunar infarction. Stroke 33: 1493-1496, 2002.
6. Shimizu H, Kiyohara Y, Kato I, et al. Plasma homocyst(e)ine concentrations and the risk of subtypes of cerebral infarction. The Hisayama study. Cerebrovasc Dis 13: 9-15, 2002.
7. Ay H, Arsava EM, Tokgozoglu SL, Ozer N, Saribas O. Hyperhomocysteinemia is associated with the presence of left atrial thrombus in stroke patients with nonvalvular atrial fibrillation. Stroke 34: 909-912, 2003.
8. Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke 34: 1258-1261, 2003.
9. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113, 1995.
10. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98: 2520-2526, 1998.
11. Kohara K, Fujisawa M, Ando F, et al. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: the NILS-LSA study. Stroke 34: 1130-1135, 2003.
12. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274: 1526-1533, 1995.
13. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 73: 613-621, 2001.
14. Bertsch T, Mielke O, Holy S, et al. Homocysteine in cerebrovascular disease: an independent risk factor for subcortical vascular encephalopathy. Clin Chem Lab Med 39: 721-724, 2001.
15. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 51: 285-289, 2002.
16. Giroud M, Lemesle M, Gouyon JB, Nivelon JL, Milan C, Dumas R. Cerebrovascular disease in children under 16 years of age in the city of Dijon, France: a study of incidence and clinical features from 1985 to 1993. J Clin Epidemiol 48: 1343-1348, 1995.
17. Hogeveen M, Blom HJ, Van Amerongen M, Boogmans B, Van Beynum IM, Van De Bor M. Hyperhomocysteinemia as risk factor for ischemic and hemorrhagic stroke in newborn infants. J Pediatr 141: 429-431, 2002.
18. Spence JD, Howard VJ, Chambless LE, et al. Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. Neuroepidemiology 20: 16-25, 2001.
19. VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial. Rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis 13: 120-126, 2002.